Synapse - Works

Results (1243)

Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors

Journal Article

Matulewicz, R. S.; Baky, F.; Liso, N.; Williams, B. M.; Porwal, S.; Assel, M.; Carver, B. S.; Bajorin, D. F.; Motzer, R. J.; Bosl, G. J.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Health-related quality-of-life profile and clinical outcomes in first-line advanced renal cell carcinoma: A modeling analysis based on the CheckMate 9ER study

Journal Article

Cella, D.; Derosa, M.; Floden, L.; Giles, R. H.; Lothgren, M.; Ogareva, A.; Powles, T.; Purnajo, I.; Choueiri, T. K.; Bergerot, C.; more...
ESMO Open (2025)

Fulltext@MSK | Save

Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post-immune-oncology and vascular endothelial growth factor receptor targeted therapies

Journal Article

Shah, N. J.; Sura, S.; Shinde, R.; Shi, J.; Bupathi, M.; Vickery, D.; Motzer, R. J.
Cancers (2025)

Fulltext@MSK | Save

INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC)

Meeting Abstract

Motzer, R. J.; Braun, D. A.; Powles, T.; Gurney, H.; Fong, L.; George, D. J.; Haas, N. B.; McDermott, D. F.; Shuch, B. M.; Meehan, R.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)

Meeting Abstract

Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605)

Meeting Abstract

Shah, N. J.; Bupathi, M.; Garmezy, B.; McKay, R. R.; Ornstein, M. C.; Figlin, R. A.; Picus, J.; Rank, B. H.; Barata, P. C.; Hammers, H. J.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Outcomes with first-line ipilimumab and nivolumab for patients with metastatic renal cell carcinoma by number of doses

Meeting Abstract

Doshi, S. D.; Sanmiguel, A. L.; Knezevic, A.; Kotecha, R. R.; Shah, N. J.; Carlo, M.; Feldman, D. R.; Motzer, R. J.; Voss, M. H.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and novel immunotherapy agents for advanced clear cell renal cell carcinoma (ccRCC)

Meeting Abstract

Suárez, C.; Albiges, L.; Beckermann, K.; Hammers, H. J.; Stadler, W. M.; Miller, W. H. Jr; Rojas, C.; Peer, A.; Goh, J. C.; Park, S. H.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib + pembrolizumab (L+P) in the phase 3 CLEAR trial

Meeting Abstract

Grünwald, V.; Keizman, D.; Bedke, J.; Staehler, M. D.; Matveev, V. B.; George, S.; Hutson, T. E.; Vaishampayan, U. N.; Merchan, J. R.; Eto, M.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial

Meeting Abstract

Motzer, R. J.; Escudier, B.; Burotto, M.; Powles, T.; Apolo, A. B.; Bourlon, M. T.; Shah, A. Y.; Porta, C.; Suárez, C.; Barrios, C. H.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save